69 related articles for article (PubMed ID: 29095654)
1. Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.
Franklin M; Burns L; Perez S; Yerragolam D; Makenbaeva D
Curr Med Res Opin; 2018 Feb; 34(2):353-360. PubMed ID: 29095654
[TBL] [Abstract][Full Text] [Related]
2. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
3. Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study.
Huang CE; Lee KD; Chang JJ; Tzeng HE; Huang SH; Yu LH; Chen MC
Oncologist; 2024 Jan; 29(1):e81-e89. PubMed ID: 37561957
[TBL] [Abstract][Full Text] [Related]
4. Impact of monthly prescription cap on medication persistence among patients with hypertension, hyperlipidemia, or diabetes.
Wang CC; Wei D; Farley JF
J Manag Care Pharm; 2013 Apr; 19(3):258-68. PubMed ID: 23537460
[TBL] [Abstract][Full Text] [Related]
5. The incidence and prevalence of diabetes mellitus and related atherosclerotic complications in Korea: a National Health Insurance Database Study.
Koo BK; Lee CH; Yang BR; Hwang SS; Choi NK
PLoS One; 2014; 9(10):e110650. PubMed ID: 25329714
[TBL] [Abstract][Full Text] [Related]
6. Association of Longitudinal Activity Measures and Diabetes Risk: An Analysis From the National Institutes of Health All of Us Research Program.
Perry AS; Annis JS; Master H; Nayor M; Hughes A; Kouame A; Natarajan K; Marginean K; Murthy V; Roden DM; Harris PA; Shah R; Brittain EL
J Clin Endocrinol Metab; 2023 Apr; 108(5):1101-1109. PubMed ID: 36458881
[TBL] [Abstract][Full Text] [Related]
7. Kinship analysis of type 2 diabetes mellitus familial aggregation in Taiwan.
Liao PJ; Ting MK; Kuo CF; Ding YH; Lin CM; Hsu KH
Biomed J; 2023 Aug; 46(4):100549. PubMed ID: 35863666
[TBL] [Abstract][Full Text] [Related]
8. Trends in Diabetes Medication Taking and Incidence of Depression in Patients with Type 2 Diabetes: A Retrospective Cohort Study from 2010 to 2018.
Chou LN; Raji MA; Yu X; Kuo YF
Int J Behav Med; 2024 Apr; 31(2):192-201. PubMed ID: 36952218
[TBL] [Abstract][Full Text] [Related]
9. The impact of physical disability on the risk of gastric cancer incidence in elderly patients with diabetes: a focus on regional disparity.
Choi M; Lee WR; Han KT; Kim W
Cancer Causes Control; 2024 Apr; 35(4):705-710. PubMed ID: 38066202
[TBL] [Abstract][Full Text] [Related]
10. Association of pancreatitis with risk of diabetes: analysis of real-world data.
Ba DM; Chinchilli VM; Cozzi AM; Bradley DP; Pichardo-Lowden AR
Front Clin Diabetes Healthc; 2023; 4():1326239. PubMed ID: 38264059
[TBL] [Abstract][Full Text] [Related]
11. Incident Cancer Risk in Patients with Incident Type 2 Diabetes Mellitus in Hungary (Part 1).
Abonyi-Tóth Z; Rokszin G; Fábián I; Kiss Z; Jermendy G; Kempler P; Lengyel C; Wittmann I; Molnár GA; Sütő G
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730697
[TBL] [Abstract][Full Text] [Related]
12. Trends and Patterns of Urodynamic Studies in U.S. Males, 2000-2012.
Conover MM; Jonsson Funk M; Kinlaw AC; Borawski KM; Wu JM
PLoS One; 2015; 10(7):e0133657. PubMed ID: 26196514
[TBL] [Abstract][Full Text] [Related]
13. The hemorrhage risk of dasatinib therapy.
Pontarollo G; Reinhardt C
Blood; 2023 Jun; 141(24):2917-2918. PubMed ID: 37318908
[No Abstract] [Full Text] [Related]
14. Hyperlipidemia-Attributed Deaths in the U.S. in 2018-2021.
Zheutlin AR; Harris BRE; Stulberg EL
Am J Prev Med; 2024 Jun; 66(6):1075-1077. PubMed ID: 38408688
[No Abstract] [Full Text] [Related]
15. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.
Iriyama N; Sugimoto KJ; Sato E; Takaku T; Tokuhira M; Nakazato T; Ishikawa M; Fujita H; Fujioka I; Kimura Y; Asou N; Kizaki M; Komatsu N; Hatta Y; Kawaguchi T
Med Oncol; 2018 Sep; 35(11):142. PubMed ID: 30194496
[TBL] [Abstract][Full Text] [Related]
17. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.
Cole AL; Wood WA; Muluneh B; Lund JL; Elston Lafata J; Dusetzina SB
JCO Oncol Pract; 2020 May; 16(5):e443-e455. PubMed ID: 32196424
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib-Induced Diabetes Mellitus in a Young Female with Chronic Myeloid Leukemia.
Ismail AS; Yassin MA
Cureus; 2020 Sep; 12(9):e10277. PubMed ID: 33042713
[TBL] [Abstract][Full Text] [Related]
19. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
Minson AG; Cummins K; Fox L; Costello B; Yeung D; Cleary R; Forsyth C; Tatarczuch M; Burbury K; Motorna O; Shortt J; Fleming S; McQuillan A; Schwarer A; Harrup R; Holmes A; Ratnasingam S; Chan KL; Hsu WH; Ashraf A; Putt F; Grigg A
Blood Adv; 2019 Apr; 3(7):1084-1091. PubMed ID: 30944100
[TBL] [Abstract][Full Text] [Related]
20. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
Wang Y; Travers RJ; Farrell A; Lu Q; Bays JL; Stepanian A; Chen C; Jaffe IZ
PLoS One; 2023; 18(11):e0294438. PubMed ID: 37983208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
